Jeffrey Scott Sherman - May 2, 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Signature
/s/ Ali Olivo, Attorney-in-Fact
Stock symbol
NEO
Transactions as of
May 2, 2025
Transactions value $
$150,104
Form type
4
Date filed
5/6/2025, 04:08 PM
Previous filing
Feb 25, 2025
Next filing
May 13, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sherman Jeffrey Scott Chief Financial Officer 9490 NEOGENOMICS WAY, FORT MYERS /s/ Ali Olivo, Attorney-in-Fact 2025-05-06 0001463145

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NEO Common Stock Purchase $150K +20K +14.44% $7.51 158K May 2, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NEO Stock Option (Right to Buy) 249K May 2, 2025 Common Stock 249K $11.62 Direct F2
holding NEO Stock Option (Right to Buy) 73K May 2, 2025 Common Stock 73K $19.65 Direct F3
holding NEO Restricted Stock Unit 26K May 2, 2025 Common Stock 26K $0.00 Direct F4, F5
holding NEO Performance Stock Unit 39K May 2, 2025 Common Stock 39K $0.00 Direct F5, F6
holding NEO Stock Option (Right to Buy) 77.9K May 2, 2025 Common Stock 77.9K $16.45 Direct F7
holding NEO Performance Stock Unit 46.6K May 2, 2025 Common Stock 46.6K $0.00 Direct F5, F8
holding NEO Restricted Stock Unit 59.4K May 2, 2025 Common Stock 59.4K $0.00 Direct F5
holding NEO Restricted Stock Unit 31.1K May 2, 2025 Common Stock 31.1K $0.00 Direct F5, F9
holding NEO Stock Option (Right to Buy) 215K May 2, 2025 Common Stock 215K $13.05 Direct F10, F11
holding NEO Restricted Stock Unit 126K May 2, 2025 Common Stock 126K $0.00 Direct F5, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 1,430 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
F2 On December 5, 2022, Mr. Sherman was granted 249,169 stock options. The options vest ratably over four years with the first tranche vesting on December 7, 2023.
F3 On May 11, 2023, Mr. Sherman was granted 73,016 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F4 On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F5 Once vested, the shares of common stock are not subject to expiration.
F6 On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
F7 On February 23, 2024, Mr. Sherman was granted 77,913 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F8 On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company
F9 On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F10 This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F11 On February 21, 2025, Mr. Sherman was granted 214,900 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F12 On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.